Patent ID: 8568988

Claim:
A method for determining complete remission or non-remission in a patient with acute myeloid leukemia (AML) after chemotherapy, which comprises measuring the level of CFH (complement factor H) or ApoH (apolipoprotein H) in a biological sample selected from the group consisting of blood, serum and plasma from the AML patient by immunoassay, wherein a level of 500-700 μg/ml of CFH or ApoH indicates that the patient is in a non-remission in AML, wherein a similar level of CFH or ApoH compared to the levels thereof in blood, serum or plasma from a normal human indicates that the patient achieves complete remission in AML, and wherein the similar level of CFH or ApoH to the normal human is between +50 μg/ml and −50 μg/ml of a level of CFH or ApoH in the normal human.